Drug General Information |
Drug ID |
D0PP6Y
|
Former ID |
DIB019226
|
Drug Name |
compound 13a
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C19H18N6O
|
InChI |
InChI=1S/C19H18N6O/c1-3-17(24-5-7-26-8-6-24)4-2-14(1)16-9-20-19-18(12-23-25(19)13-16)15-10-21-22-11-15/h1-4,9-13H,5-8H2,(H,21,22)
|
InChIKey |
WCDLCPLAAKUJNY-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
TGF-beta type II receptor |
Target Info |
Inhibitor |
[1]
|
activin A receptor, type I |
Target Info |
Inhibitor |
[1]
|
AMP-activated protein kinase |
Target Info |
Inhibitor |
[1]
|
Activin receptor-like kinase-1 |
Target Info |
Inhibitor |
[1]
|
Bone morphogenetic protein receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Proteoglycans in cancerhsa04010:MAPK signaling pathway
|
FoxO signaling pathway
|
TGF-beta signaling pathway
|
Osteoclast differentiation
|
Hippo signaling pathway
|
Adherens junction
|
Chagas disease (American trypanosomiasis)
|
HTLV-I infection
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Colorectal cancer
|
Pancreatic cancer
|
Chronic myeloid leukemiahsa04068:FoxO signaling pathway
|
Regulation of autophagy
|
mTOR signaling pathway
|
AMPK signaling pathway
|
Circadian rhythm
|
Insulin signaling pathway
|
Adipocytokine signaling pathway
|
Oxytocin signaling pathway
|
Glucagon signaling pathway
|
Non-alcoholic fatty liver disease (NAFLD)
|
Hypertrophic cardiomyopathy (HCM)hsa04060:Cytokine-cytokine receptor interaction
|
Signaling pathways regulating pluripotency of stem cells
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_25:FSH Signaling Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathwayP00052:TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
VEGF and VEGFR signaling network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network
|
ALK1 signaling events
|
TGF-beta receptor signalingalk1_2pathway:ALK1 pathway
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferationR-HSA-2173789:TGF-beta receptor signaling activates SMADs
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
TGFBR2 Kinase Domain Mutants in Cancer
|
TGFBR1 KD Mutants in Cancer
|
TGFBR1 LBD Mutants in CancerR-HSA-1445148:Translocation of GLUT4 to the plasma membrane
|
Macroautophagy
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
TP53 Regulates Metabolic Genes
|
WikiPathways
|
Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
Signaling by VEGF
|
AngiogenesisWP560:TGF Beta Signaling Pathway
|
MAPK Signaling Pathway
|
TGF beta Signaling Pathway
|
NRF2 pathway
|
Nuclear Receptors Meta-Pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
Signaling by TGF-beta Receptor Complex
|
miR-targeted genes in squamous cell - TarBase
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
miR-targeted genes in adipocytes - TarBase
|
Integrated Breast Cancer PathwayWP481:Insulin Signaling
|
Energy dependent regulation of mTOR by LKB1-AMPK
|
JAK/STAT
|
BDNF signaling pathway
|
Leptin signaling pathway
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
SREBP signalling
|
Signaling by Insulin receptor
|
TOR Signaling
|
AMPK SignalingWP474:Endochondral Ossification
|
Ectoderm Differentiation
|
Mesodermal Commitment Pathway
|
Endoderm Differentiation
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Signaling by BMP
|
Integrated Breast Cancer Pathway
|
Heart Development
|
BMP Signalling and Regulation
|
References |
REF 1 | Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. |